Aratana Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aratana Therapeutics generated cash of -$11,261,000, which is more than the previous year. Cash used in financing activities reached the amount of -$13,673,000 last year. Net change in cash is therefore -$25,436,000.
Cash Flow
| 2013 | -16.15M | -29.23M | 72.49M |
|---|---|---|---|
| 2014 | -32.18M | -100.12M | 100.97M |
| 2015 | -38.49M | 33.66M | 21.89M |
| 2016 | -11.32M | 57.28M | 14.63M |
| 2017 | -38.18M | -5.75M | 23.47M |
| 2018 | -11.26M | -493K | -13.67M |
PETX Cash Flow Statement (2013 – 2018)
| 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 67.21M | 87.65M | 26.75M | 9.82M | 41.08M | 13.97M |
Operating activities | ||||||
Net income | -14.72M | -47.51M | -33.57M | -84.05M | -38.81M | -4.28M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 2.00M | 1.67M | 1.46M | 1.96M | 2.08M | 395K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 1.02M |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 1.02M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 202K | -2.31M | -27K | 281K | -102K | 0 |
Inventories | -499K | -3.18M | -15.01M | -879K | -372K | 0 |
Accounts payable | -6.54M | 62K | 6.18M | -117K | -1.14M | 1.52M |
Cash generated by operating activities | -11.26M | -38.18M | -11.32M | -38.49M | -32.18M | -16.15M |
Investing activities | ||||||
Purchases Of Investments | -4.21M | -3.73M | -229.93M | -2.05B | -372.53M | -5.16M |
Investments In Property Plant And Equipment | 0 | -1K | -72K | -2.24M | -471K | -94K |
Acquisitions Net | 0 | 0 | 0 | 0 | -12.07M | -30.99M |
Cash generated by investing activities | -493K | -5.75M | 57.28M | 33.66M | -100.12M | -29.23M |
Financing activities | ||||||
Common Stock Issued | 24.22M | 27.46M | 14.58M | 0 | 0 | 19.75M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -4.53M |
Repurchases of common stock | -41.43M | -66.86M | -87.30M | -7K | -1.08M | -41.08M |
Repayments of term debt | -36.5M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -13.67M | 23.47M | 14.63M | 21.89M | 100.97M | 72.49M |
Net Change In Cash | -25.43M | -20.43M | 60.55M | 16.93M | -31.26M | 27.11M |
Cash at end of period | 41.78M | 67.21M | 87.30M | 26.75M | 9.82M | 41.08M |
| Data source | Data source | Data source | Data source | Data source | Data source |